Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Corticale

IIT spin-off selling SiNAPS CMOS neural probes with 1,024 active electrodes for high-density brain recording, an option on brain-computer interfaces.

Genoa, Italy, EuropeMedTech & devices, Neurotechnology / neural probesItaly (presumed, e.g. Milan Regional)
Stage
SeedNo documented AI
Product
On the marketNone known
Funding raised
$2.2Mdisclosed
Founded
20215 years ago
Founders
4Luca, Gian…
Global score
4.5Grade DRank 63 of 151

Overview

A spin-off from the Istituto Italiano di Tecnologia (IIT) in Genoa, Corticale develops high-density neural probes to record brain activity, paving the way for brain-computer interfaces.

Traction

None known

The website has a products section and terms of sale, but no customer or user lab is published (conservative estimate).

Market

Brain-computer interfaces / neural probes

Neuroscience labs buy high-density probes to record large neural populations, a market shaped by Neuropixels. Probe makers can later move into clinical brain-computer interfaces, where value is much larger but regulation is heavy. Buyers today are academic and pharma research labs funded by grants. No customer is published.

Addressable market

2025
$2.4B
2030
$4.7B
+14.4% a year

Brain-computer interfaces / neural probes: $2.4bn in 2025, +14.4%/year, $4.7bn in 2030 (Coherent Market Insights).

Customers

Neuroscience research labs, pharma neuro-research, neurotech companies

Who signs the cheque

Principal investigators (grant-funded), pharma R&D managers

Geographies

  • Italy
  • Europe

Drivers

  • Large neuroscience initiatives and funding
  • Demand for higher channel counts
  • BCI commercial momentum

Headwinds

  • Competition from Neuropixels
  • Narrow research market
  • Long BCI regulatory path

The brain-computer interface market is estimated at $2.40bn in 2025 (+14.4%/year to 2032) according to Coherent Market Insights; most sources converge on $2.4–3.4bn, with research neural probes a niche within it.

Scalability 6/10. Probes that can be sold to labs worldwide, but a research niche, and medical devices need certification.

Market source: m.giikorea.co.kr

Technology

Category

Neurotechnology hardware (CMOS neural probes)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

in market

How it works

SiNAPS probes integrate 1,024 independent active electrodes spaced 30 µm apart on a CMOS chip. Active electrode design allows high-density recording across the probe.

Moat

Strong technical IP and IIT know-how (founder also co-founded 3Brain); commercial moat unproven.

Differentiation

Fully active, independent electrodes on CMOS vs passive or switch-matrix designs (claimed advantage).

Integration points

  • Electrophysiology acquisition systems
  • Brain organoid and in-vitro platforms
  • BCI developers
  • Neuro-AI decoding software

Depends on

  • CMOS foundry access
  • Research funding cycles
  • Medical certification for clinical use

Use of AI

No use of AI mentioned

Product in detail

SiNAPS probe on a CMOS chip with 1,024 independent active electrodes spaced 30 µm apart.

Business

Model
Sale of probes and systems to labs (terms of sale online).
Revenue logic
Per-probe consumables plus acquisition hardware (pricing not disclosed).
Go-to-market
Direct online sales and academic network.

Next milestones

  1. Publish reference labs and sales
  2. Strategic BCI partnership
  3. Seed extension or EU grant

Key risks

  • No published customers
  • Neuropixels competition
  • Unclear path to BCI

Opportunities

4 found in the network

Concrete moves for Corticale inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Co-development 2
  • Investors 2

Co-development2

An integration or joint product

Combine soft cortical electrodes with CMOS high-density readout

Neurosoft makes soft, stretchable surface electrodes and Corticale masters high-density active CMOS electronics; both are European spin-offs heading toward BCIs. A joint project (e.g., an EU grant) on high-channel soft interfaces with active readout combines complementary know-how.

25%confidence

Evidence from the records

  • “Soft, stretchable cortical electrodes (SoftECoG) made of elastic materials, implantable in a minimally invasive way and suitable for industrial production.”
  • “SiNAPS probe on a CMOS chip with 1,024 independent active electrodes spaced 30 µm apart.”
If it works
A joint EU research proposal and possible supply of readout ICs.
First step
Organise a technical call between both CTOs to map complementarities.

Organoid electrophysiology kit with defined media

Brain organoids from pluripotent stem cells need standardised culture and high-density recording. Pairing Defined Bioscience's media with Corticale probes creates a reproducible workflow for labs that already buy from Defined Bioscience.

20%confidence

Evidence from the records

  • “Range of 11 media and reagents on sale, used by laboratories (UC San Diego, Tufts, Penn State, Vala Sciences…).”
  • “Products and terms of sale online, but no customer published.”
If it works
Co-marketing to stem-cell labs and first published Corticale users.
First step
Propose a joint application note with one Defined Bioscience lab.

Investors2

A fund whose thesis fits

Approach CDP Venture Capital via MON5 or Proxima Robotics

CDP Venture Capital invests from pre-seed to Series A in Italy and Europe and backed MON5 and Proxima Robotics in the network, providing warm paths for an Italian deep-tech company.

30%confidence

Evidence from the records

  • “Primo Capital (lead), Forward Factory (CDP Venture Capital), GDA Invest SCSp, Cloud Accelerator (conversion)”
  • “~€2M (Giuseppe Santella) + research funding (IIT, NIH BRAIN Initiative)”
If it works
An Italian institutional lead for a seed extension.
First step
Ask MON5's founders for an introduction to CDP's investment team.

Pitch Breakout Ventures' neurotech thesis via ZymoChem

Breakout Ventures backs science-driven founders including in neurotech at seed/Series A, though its focus is North America. It led ZymoChem's Series A in the network.

15%confidence

Evidence from the records

  • “Backs founders pairing technology with science (drug discovery, climate, neurotech, lab automation).”
  • “Cutting-edge IIT technology”
If it works
A US investor if Corticale establishes a US presence.
First step
Ask ZymoChem's founders for an introduction.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Italy's national VC institution, investing pre-seed to Series A and running accelerators such as Forward Factory (MON5, Proxima Robotics).

Italian neural probes (neurotechnology) at seed: Italian deep tech with a product range. No published customers yet.

55%confidence

Evidence from the records

  • “Neurotechnology / neural probes”
  • “Italy”
Intro path
Proxima Robotics (CDP portfolio, Italian deep-tech peer)
First step
Apply to a CDP life-science accelerator or request a direct seed meeting.

EIC Fund: the European Innovation Council's equity arm, investing €0.5M-30M in breakthrough European deep tech alongside EIC Accelerator grants.

Italian neural probes at seed: neurotech deep tech with a product range.

40%confidence

Evidence from the records

  • “Neurotechnology / neural probes”
  • “Italy”
Intro path
Lampsy Health (EIC portfolio, neurology peer)
First step
Apply to EIC Accelerator.

US investor with no profile in our data; participated in Neurosoft Bioelectronics' oversubscribed $7.5M seed.

Italian neural probes at seed — direct neurotech analogue to Neurosoft.

35%confidence

Evidence from the records

  • “Neurosoft Bioelectronics”
  • “Neurotechnology / neural probes”
  • “The website has a products section and terms of sale, but no customer or user lab is published (conservative estimate).”
Intro path
Founder-to-founder intro via Neurosoft Bioelectronics (network portfolio company of IAG Capital Partners).
First step
Ask Neurosoft for an introduction.

European Innovation Council's Horizon Europe programme, funding deep-tech startups and SMEs with EIC Accelerator grants plus EIC Fund equity.

Italian neural probes: health deep tech; commercial traction unclear.

30%confidence

Evidence from the records

  • “Neurotechnology / neural probes”
  • “Seed”
Intro path
Lampsy Health (EIC grantee, neuro peer)
First step
Strengthen market evidence before applying.

Investor with an empty profile; participated in Neurosoft Bioelectronics' oversubscribed $7.5M seed (2026).

IIT spin-off with high-density neural probes: closest network company to Neurosoft's neural-interface field.

30%confidence

Evidence from the records

  • “Neurotechnology / neural probes”
  • “Seed”
Intro path
Neurosoft Bioelectronics founders.
First step
Ask Neurosoft how Skybound engaged.

Investment arm linked to Protocol Labs; the only recorded data point is the oversubscribed $7.5M seed of brain-interface company Neurosoft.

IIT spin-off making high-density neural probes, adjacent to Neurosoft's neural-interface field. Fit rests only on the single neurotech data point.

30%confidence

Evidence from the records

  • “Neurotechnology / neural probes”
  • “paving the way for brain-computer interfaces”
Intro path
Neurosoft Bioelectronics founders (same field).
First step
Ask Neurosoft's team how PL Capital diligenced the round, then pitch Corticale.

Milan-based Italian venture manager that led OT-security company MON5's 2026 capital increase.

IIT Genoa neural-probe spin-off: Italian deep tech, but medtech is untested for Primo.

30%confidence

Evidence from the records

  • “A spin-off from the Istituto Italiano di Tecnologia (IIT) in Genoa”
  • “Italy”
First step
Ask Primo whether it invests in medtech before pitching.

Swiss innovation agency funding Swiss startups; supported Neurosoft Bioelectronics through its Swiss Accelerator grant.

Italian neural probes — neurotech; would need a Swiss entity.

20%confidence

Evidence from the records

  • “"Switzerland"”
  • “Neurotechnology / neural probes”
  • “The website has a products section and terms of sale, but no customer or user lab is published (conservative estimate).”
Intro path
Founder-to-founder intro via Neurosoft Bioelectronics (network portfolio company of Innosuisse).
First step
Only if a Swiss subsidiary is planned.

Manchester/Leeds/Sheffield university-founded investor (£312M) backing spin-outs and IP-rich businesses in the North of England.

Italian neural probes — IP-rich; non-UK.

15%confidence

Evidence from the records

  • “IP-rich businesses”
  • “Neurotechnology / neural probes”
  • “The website has a products section and terms of sale, but no customer or user lab is published (conservative estimate).”
Intro path
Founder-to-founder intro via Ocuwell Limited (network portfolio company of Northern Gritstone).
First step
Low priority.

Investment analysis

4.5D

Grade D

Rank 63 of 151

Disruption7.0/10
Business model3.0/10
Market4.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Remarkable technology but unclear business model: speculative.

Disruption

7/10

High-density neural probes from IIT: cutting-edge technology for neuroscience.

Business model

3/10

Products and terms of sale online, but no customer published.

Market

4/10

TAM $2.4bn → base 4; scalability 6/10 (neutral); no international presence: no customer published → 4/10.

Risk

7/10

Lower is better

High risk: narrow research market, competition (Neuropixels) and a distant BCI path.

Strengths

  • Cutting-edge IIT technology
  • Option on brain-computer interfaces

Risks

  • Customers not published
  • Competition from Neuropixels

Funding

$2.2M, disclosed
  1. ~2021

    seed (single investor)€2M

    Giuseppe Santella

  2. antérieur

    research grantsnot specified

    IIT, NIH BRAIN Initiative (upstream research)

  3. 2024

    regional grantnot specified

    PR FESR Liguria 2021-2027 (Action 1.2.3)

  4. 2023

    programnon-monetary

    Intesa Sanpaolo Elite Lounge

Amount used in the study. €2M seed; research and regional funding not quantified.

Note. ~€2M private + research and regional funding

verified: no 2025-2026 funding round found; peer-reviewed study of the SiNAPS probes (April 2025) and goal of a first-in-human trial in 2026. SWC Italy qualification not found.

Team

  • Luca Berdondini

    Co-founder

    Principal Investigator at IIT (Microtechnologies for Neuroelectronics); co-founder of 3Brain AG.

  • Gian Nicola Angotzi

    Co-founder & scientific director

    IIT researcher in CMOS neuroelectronics.

  • Fabio Boi

    Co-founder (researcher behind the project)

    IIT neurotechnology researcher.

  • Giuseppe Santella

    Chairman / investor

    Entrepreneur who funded the company (€2M) and then became chairman.

Sources

Regional final
Italy (presumed, e.g. Milan Regional)
Identification confidence
high
Founding year: 2021 (medium confidence)
Press: IIT spin-off "born in 2021"; Italian register not consulted opentalk.iit.it
  1. 1innovationorigins.com/en/italian-start-up-to-launch-technology-that-records-the-b
  2. 2liguria.bizjournal.it/2023/04/14/le-startup-genovesi-buddyfit-e-corticale-selezio
  3. 3panorama.it/tempo-libero/tecnologia/chip-cervello-cura-paralisi
  4. 4businesswire.com/news/home/20250428485361/en
  5. 5massdevice.com/corticale-study-results-sensors-bci-development/

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet